- Home
- TSN vs GMAB Comparison
TSN vs GMAB Comparison
Compare TSN & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSN
- GMAB
- Stock Information
- Founded
- TSN 1935
- GMAB 1999
- Country
- TSN United States
- GMAB Denmark
- Employees
- TSN N/A
- GMAB N/A
- Industry
- TSN Meat/Poultry/Fish
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- TSN Consumer Staples
- GMAB Health Care
- Exchange
- TSN Nasdaq
- GMAB Nasdaq
- Market Cap
- TSN 19.7B
- GMAB 17.4B
- IPO Year
- TSN N/A
- GMAB N/A
- Fundamental
- Price
- TSN $52.10
- GMAB $28.78
- Analyst Decision
- TSN Hold
- GMAB Strong Buy
- Analyst Count
- TSN 10
- GMAB 7
- Target Price
- TSN $62.30
- GMAB $41.17
- AVG Volume (30 Days)
- TSN 2.6M
- GMAB 2.5M
- Earning Date
- TSN 11-10-2025
- GMAB 11-06-2025
- Dividend Yield
- TSN 3.84%
- GMAB N/A
- EPS Growth
- TSN N/A
- GMAB 77.72
- EPS
- TSN 2.20
- GMAB 21.62
- Revenue
- TSN $54,146,000,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- TSN $3.71
- GMAB $24.92
- Revenue Next Year
- TSN $2.34
- GMAB $15.97
- P/E Ratio
- TSN $23.68
- GMAB $1.33
- Revenue Growth
- TSN 1.99
- GMAB 32.97
- 52 Week Low
- TSN $50.56
- GMAB $17.24
- 52 Week High
- TSN $65.95
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- TSN 46.12
- GMAB 39.95
- Support Level
- TSN $50.56
- GMAB $29.57
- Resistance Level
- TSN $52.64
- GMAB $29.30
- Average True Range (ATR)
- TSN 0.97
- GMAB 0.64
- MACD
- TSN 0.06
- GMAB -0.44
- Stochastic Oscillator
- TSN 57.46
- GMAB 8.54
About TSN Tyson Foods Inc.
Tyson Foods is a protein-focused food producer, selling raw chicken, beef, pork, and prepared foods. Chicken and beef are its two largest segments, each composing about one third of US sales. Prepared foods constituted 18% of fiscal 2024 sales and include brands like Tyson, Jimmy Dean, Hillshire Farm, Ball Park, and Sara Lee. However, most of these are in product categories rife with competition where Tyson does not have a massive market share lead. Tyson sells some products overseas, but the international segment accounts for just 4% of total revenue. The company is an active acquirer, with more recent years' purchases focused on international and food-service markets.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.